Open AccessPrescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer
Author(s) -
Hui Zhao,
Xiudong Lei,
Jiangong Niu,
Ning Zhang,
Zhenfeng Duan,
Mariana ChavezMacGregor,
Sharon H. Giordano
Publication year - 2021
Publication title -
jco oncology practice
Language(s) - English
Resource type - Journals
eISSN - 2688-1535
pISSN - 2688-1527
DOI - 10.1200/op.20.00248
Subject(s) - medicine , breast cancer , tamoxifen , odds ratio , hormonal therapy , cancer , medicare part d , medical prescription , oncology , prescription drug , pharmacology
Tamoxifen and aromatase inhibitors (AIs) are used as adjuvant hormonal therapy (AHT) for early-stage hormone receptor-positive (HR+) breast cancer. Treatment for 5 years reduces cancer mortality by 30%. Despite this benefit, adherence to AHT has been suboptimal. Here, we evaluated AHT initiation and patient adherence in women with private health insurance.